NOTICE: SWITCHING PATIENTS FROM TENOFOVIR 300MG/EMTRICITABINE 200MG BACK ONTO ABACAVIR/LAMIVUDINE AND ZIDOVUDINE 300MG/LAMIVUDINE 150MG DUAL COMBINATION FORMULATIONS

In 2019, a circular was distributed (see Reference 2019/06/07/AMD/EDP/011) recommending that certain patients on Abacavir (ABC) 600mg/Lamivudine (3TC) 300mg and Zidovudine (AZT) 300mg/3TC 150mg dual formulation tablets be switched to Tenofovir (TDF) 300mg/Emtricitabine (FTC) 200mg dual combination tablets. This supply challenge has since been resolved.

There is currently a supply constraint with TDF 300mg/FTC 200mg due to increasing demand. It is therefore recommended that patients who were previously switched to TDF/FTC in 2019, be switched back to their original ABC/3TC or AZT/3TC dual combination tablets.

Comments may be submitted via e-mail:

Stock queries:
Ms Maureen Masinge
Tel: 012 395 9683
E-mail: Maureen.Masinge@health.gov.za

Clinical queries:
Essential Drugs Programme
E-mail: SAEDP@health.gov.za

Kind regards

MS KHADIJA JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
DATE: 13/3/2020

---

1 Notice: Recommendations for the rational use of abacavir 600mg/lamivudine 300mg and zidovudine 300mg/lamivudine 150mg dual combination formulations.